Inhibrx Biosciences, Inc.
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
INBX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 11025 N. TORREY PINES ROAD, SUITE 140, 92037 LA JOLLA
- Website:
- https://inhibrx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates for patients with life-threatening conditions. The company leverages its expertise in target biology and protein engineering to create innovative treatments, aiming to improve upon established discoveries in biotherapeutics. Its clinical-stage pipeline is primarily focused on oncology, with therapeutic candidates in trials for cancers such as Sarcoma, Head and Neck Cancer, and Chondrosarcoma. Inhibrx operates with an agile approach, combining deep scientific and clinical experience to address unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inhibrx Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inhibrx Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inhibrx Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
